ACE2受体:在COVID-19中是一个潜在的药理目标
Yaping Zhu1, Shungeng Zhang2, Zeguang Wang2
1Department of Gastrointestinal Surgery, Jining First People's Hospital, Jining, China.
Current protein & peptide science
|August 17, 2023
概括
复合 ангиотензин转化酶2 (ACE2) 疗法对心血管和脏的保护有希望. 基于ACE2的策略,包括诱和基因表达调节器,正在成为COVID-19的潜在治疗方法.
科学领域:
- 生物化学 生物化学
- 心血管科学 心血管科学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 病毒学 病毒学
背景情况:
- ангиотензин转化酶2 (ACE2) 在心血管和功能中起着至关重要的作用.
- ACE2受体与2019年新冠肺炎疾病 (COVID-19) 的病原发生有关.
- 在临床前研究中,重组ACE2已经证明了治疗潜力.
研究的目的:
- 综合审查关于ACE2结构,分布和功能的文献.
- 探索基于ACE2治疗心血管和脏疾病的潜力.
- 确定涉及ACE2的COVID-19有前途的治疗策略2.
主要方法:
- 对复合ACE2研究的文献综述2.
- 对ACE2在心血管和病理生理学中的作用的分析.
- 评估ACE2在COVID-19病变发生过程中的参与.
主要成果:
- 重组ACE2注射增加了循环ACE2活性.
- 通过ACE2治疗可以减少心脏缩,纤维化,血压和白蛋白尿.
- 在COVID-19病变发生过程中ACE2的作用激发了人们对基于ACE2的治疗方法的兴趣.
结论:
- ACE2诱 (sACE2,hrsACE2,ACE2衍生的) 是潜在的COVID-19治疗方法.
- 降低ACE2或TMPRSS2基因表达的药物可能是有益的.
- 表观遗传修饰剂和传统中医药为COVID-19治疗提供了新的途径.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
G Protein-coupled Receptors
12.2K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
203
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
203


